ArticleEpilepsy currents
Refractory epilepsy: one size does not fit all.
Article in Epilepsy currents. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Stiripentol add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Felbamate add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Stiripentol add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2020Pooled it
- Felbamate add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2019Pooled it
- Subpial transection surgery for epilepsy.The Cochrane database of systematic reviews · 2018Pooled it
- Stiripentol add-on therapy for focal refractory epilepsy.The Cochrane database of systematic reviews · 2018Pooled it
- Felbamate as an add-on therapy for refractory partial epilepsy.The Cochrane database of systematic reviews · 2017Pooled it
- Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.The Cochrane database of systematic reviews · 2012Pooled it
- Remission of epilepsy after two drug failures in children: a prospective study.Annals of neurology · 2009Trial
- A pH-sensitive closed-loop nanomachine to control hyperexcitability at the single neuron level.Nature communications · 2024Article
- Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force.Epilepsia · 2023Article
- 'On-demand' gene therapy for epilepsy.Nature reviews. Neurology · 2023Article
- Gain-of-functionBrain communications · 2020Article
- Evaluation of Magnetic Resonance (MR) Findings in Patients with Refractory Epilepsy.Sisli Etfal Hastanesi tip bulteni · 2020Article
- Clobazam add-on therapy for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2019Review
- Optogenetics: the new molecular approach to control functions of neural cells in epilepsy, depression and tumors of the central nervous system.American journal of cancer research · 2018Review
- Clinical Trial of Efficacy Evaluation of Omega-3 with Risperidone on Seizures Frequency in Children with Refractory Epilepsy and Attention-Deficit/Hyperactivity Disorder.Iranian journal of child neurology · 2018Article
- And Then There Was Light: Perspectives of Optogenetics for Deep Brain Stimulation and Neuromodulation.Frontiers in neuroscience · 2017Review
- Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers.Frontiers in neurology · 2017Review
- Refractory headache: one term does not cover all--a statement of the European Headache Federation.The journal of headache and pain · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A unifying definition of refractory epilepsy has been hotly debated but, to date, has not been agreed upon. Evidence from clinical trials indicates that some patients actually are not refractory, as many will partially respond to add-on treatment or will worsen when antiepileptic drugs (AEDs) are removed. There are several important issues relating to the assessment of AED response that routinely have not been addressed in the determination of treatment responsiveness, such as incorporating baseline seizure severity, including partial response rather than solely an all-or-none response, and the consideration of variability in response over time.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.